The efficacy of human papillomavirus vaccination in young Japanese girls: the interim results of the OCEAN study

References

• Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–5. doi:10.3322/caac.21492.
   PubMed Web of Science ®Google Scholar
• WHO. WHO/UNICEF human papillomavirus (HPV) vaccine coverage estimates. BMJ Open. 2021;11(9):e052016. doi:10.1136/bmjopen-2021-052016.
   Google Scholar
• Palmer T, Wallace L, Pollock KG, Cuschieri K, Robertson C, Kavanagh K, Cruickshank M. Prevalence of cervical disease at age 20 after immunisation with bivalent HPV vaccine at age 12-13 in Scotland: retrospective population study. BMJ. 2019;365:l1161. doi:10.1136/bmj.l1161.
   PubMedGoogle Scholar
• Luostarinen T, Apter D, Dillner J, Eriksson T, Harjula K, Natunen K, Paavonen J, Pukkala E, Lehtinen M. Vaccination protects against invasive HPV-associated cancers. Int J Cancer. 2018;142:2186–87. doi:10.1002/ijc.31231.
   PubMed Web of Science ®Google Scholar
• Tota JE, Struyf F, Sampson JN, Gonzalez P, Ryser M, Herrero R, Schussler J, Karkada N, Rodriguez AC, Folschweiller N, et al. Efficacy of the AS04-adjuvanted HPV16/18 vaccine: pooled analysis of the costa rica vaccine and PATRICIA randomized controlled trials. J Natl Cancer Inst. 2020;112:818–28. doi:10.1093/jnci/djz222.
   PubMedGoogle Scholar
• Simms KT, Hanley SJB, Smith MA, Keane A, Canfell K. Impact of HPV vaccine hesitancy on cervical cancer in Japan: a modelling study. Lancet Public Health. 2020;5:e223–e234. doi:10.1016/S2468-2667(20)30010-4.
   PubMed Web of Science ®Google Scholar
• Onuki M, Matsumoto K, Satoh T, Oki A, Okada S, Minaguchi T, Ochi H, Nakao S, Someya K, Yamada N, et al. Human papillomavirus infections among Japanese women: age-related prevalence and type-specific risk for cervical cancer. Cancer Sci. 2009;100:1312–16. doi:10.1111/j.1349-7006.2009.01161.x.
   PubMed Web of Science ®Google Scholar
• Sekine M, Yamaguchi M, Kudo R, et al. Epidemiologic profile of type-specific human papillomavirus infection after initiation of HPV vaccination. Vaccines (Basel). 2020;8(3):425. doi:10.3390/vaccines8030425.
   Google Scholar
• Bogaards JA, Van Der Weele P, Woestenberg PJ, van Benthem BHB, King AJ. Bivalent Human Papillomavirus (HPV) vaccine effectiveness correlates with phylogenetic distance from HPV vaccine types 16 and 18. J Infect Dis. 2019;220:1141–46. doi:10.1093/infdis/jiz280.
   PubMed Web of Science ®Google Scholar
• Kudo R, Yamaguchi M, Sekine M, Adachi S, Ueda Y, Miyagi E, Hara M, Hanley SJB, Enomoto T. Bivalent human papillomavirus vaccine effectiveness in a Japanese population: high vaccine-type-specific effectiveness and evidence of cross-protection. J Infect Dis. 2019;219:382–90. doi:10.1093/infdis/jiy516.
   PubMed Web of Science ®Google Scholar
• Malagón T, Drolet M, Boily MC, Franco EL, Jit M, Brisson J, Brisson M. Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis. Lancet Infect Dis. 2012;12:781–89. doi:10.1016/S1473-3099(12)70187-1.
   PubMed Web of Science ®Google Scholar
• [email protected] WHOEa. Human papillomavirus vaccines: WHO position paper, May 2017-Recommendations. Vaccine. 2017;35:5753–55.
   PubMed Web of Science ®Google Scholar
• Batmunkh T, Dalmau MT, Munkhsaikhan ME, Khorolsuren T, Namjil N, Surenjav U, Toh ZQ, Licciardi PV, Russell FM, Garland SM, et al. A single dose of quadrivalent human papillomavirus (HPV) vaccine is immunogenic and reduces HPV detection rates in young women in Mongolia, six years after vaccination. Vaccine. 2020;38:4316–24. doi:10.1016/j.vaccine.2020.04.041.
   PubMed Web of Science ®Google Scholar
• Ogilvie GS, Naus M, Money DM, Dobson SR, Miller D, Krajden M, van Niekerk DJ, Coldman AJ. Reduction in cervical intraepithelial neoplasia in young women in British Columbia after introduction of the HPV vaccine: an ecological analysis. Int J Cancer. 2015;137:1931–37. doi:10.1002/ijc.29508.
   PubMed Web of Science ®Google Scholar
• Konno R, Konishi H, Sauvaget C, Ohashi Y, Kakizoe T. Effectiveness of HPV vaccination against high grade cervical lesions in Japan. Vaccine. 2018;36:7913–15. doi:10.1016/j.vaccine.2018.05.048.
   PubMed Web of Science ®Google Scholar
• Karimi-Zarchi M, Allahqoli L, Nehmati A, Kashi AM, Taghipour-Zahir S, Alkatout I. Can the prophylactic quadrivalent HPV vaccine be used as a therapeutic agent in women with CIN? A randomized trial. BMC Public Health. 2020;20:274. doi:10.1186/s12889-020-8371-z.
   PubMed Web of Science ®Google Scholar
• Kang WD, Choi HS, Kim SM. Is vaccination with quadrivalent HPV vaccine after loop electrosurgical excision procedure effective in preventing recurrence in patients with high-grade cervical intraepithelial neoplasia (CIN2-3)? Gynecol Oncol. 2013;130:264–68. doi:10.1016/j.ygyno.2013.04.050.
   PubMed Web of Science ®Google Scholar
• Benard VB, Castle PE, Jenison SA, Hunt WC, Kim JJ, Cuzick J, Lee J-H, Du R, Robertson M, Norville S, et al. Population-based incidence rates of cervical intraepithelial neoplasia in the human papillomavirus vaccine era. JAMA Oncol. 2017;3:833–37. doi:10.1001/jamaoncol.2016.3609.
   PubMed Web of Science ®Google Scholar
• De Vincenzo R, Ricci C, Conte C, Scambia G. HPV vaccine cross-protection: highlights on additional clinical benefit. Gynecol Oncol. 2013;130:642–51. doi:10.1016/j.ygyno.2013.05.033.
   PubMed Web of Science ®Google Scholar
• Burd EM. Human papillomavirus and cervical cancer. Clin Microbiol Rev. 2003;16:1–17. doi:10.1128/CMR.16.1.1-17.2003.
   PubMed Web of Science ®Google Scholar
• Naucler P, Ryd W, Törnberg S, Strand A, Wadell G, Hansson BG, Rylander E, Dillner J. HPV type-specific risks of high-grade CIN during 4 years of follow-up: a population-based prospective study. Br J Cancer. 2007;97:129–32. doi:10.1038/sj.bjc.6603843.
   PubMed Web of Science ®Google Scholar
• Ikeda S, Ueda Y, Yagi A, Matsuzaki S, Kobayashi E, Kimura T, Miyagi E, Sekine M, Enomoto T, Kudoh K, et al. HPV vaccination in Japan: what is happening in Japan? Expert Rev Vaccines. 2019;18:323–25. doi:10.1080/14760584.2019.1584040.
   PubMed Web of Science ®Google Scholar
• Suzuki S, Hosono A. No association between HPV vaccine and reported post-vaccination symptoms in Japanese young women: results of the Nagoya study. Papillomavirus Res. 2018;5:96–103. doi:10.1016/j.pvr.2018.02.002.
   PubMed Web of Science ®Google Scholar
• Hall MT, Simms KT, Lew JB, Smith MA, Brotherton JM, Saville M, Frazer IH, Canfell K. The projected timeframe until cervical cancer elimination in Australia: a modelling study. Lancet Public Health. 2019;4:e19–e27. doi:10.1016/S2468-2667(18)30183-X.
   PubMed Web of Science ®Google Scholar
• Lei J, Ploner A, Elfström KM, Wang J, Roth A, Fang F, Sundström K, Dillner J, Sparén P. HPV vaccination and the risk of invasive cervical cancer. N Engl J Med. 2020;383:1340–48. doi:10.1056/NEJMoa1917338.
   PubMed Web of Science ®Google Scholar